The EWS/FLI-1 fusion gene is characteristic of most cases of Ewing's sarcoma and has been shown to be crucial for tumor transformation and cell growth. In this study we demonstrate a drastic down-regulation of the EWS/FLI-1 protein, and a growth arrest, following serum depletion of Ewing's sarcoma cells. This indicates that growth factor circuits may be involved in regulation of the fusion gene product. Of four dierent growth factors tested, basic ®broblast growth factor (bFGF) was found to be of particular signi®cance. In fact, upon treatment of serum-depleted cells with bFGF, expression of the EWS/FLI-1 protein and growth of the Ewing's sarcoma cells were restored. In addition, a bFGFneutralizing antibody, which was con®rmed to inhibit FGF receptor (FGFR) phosphorylation, caused downregulation of EWS/FLI-1. Experiments using speci®c cell cycle blockers (thymidine and colcemide) suggest that EWS/FLI-1 is directly linked to bFGF stimulation, and not indirectly to cell proliferation. We also demonstrated expression of FGFRs in several tumor samples of Ewing's sarcoma. Taken together, our data suggest that expression of FGFR is a common feature of Ewing's sarcoma and, in particular, that the bFGF pathway may be important for the maintenance of a malignant phenotype of Ewing's sarcoma cells through up-regulating the EWS/FLI-1 protein. Oncogene (2000) 19, 4298 ± 4301.
Keywords: EWS/FLI-1; bFGF; cell growth; Ewing's sarcoma Ewing's sarcoma is genetically characterized by a balanced translocation involving the EWS gene on chromosome 22 (for review see Kovar, 1998) . In approximately 90% of the cases EWS is fused to FLI-1 on chromosome 11 underlying the translocation t(11;22) (q24;q12). The resulting hybridization gene encodes a 68-kDa chimeric protein involving the amino terminal part of EWS and the carboxy terminal part of FLI-1. FLI-1 belongs to the ETS family of transcription factors, which all contain an 85 amino acid highly conserved unique DNA binding domain, the ETS domain (Wasylyk et al., 1993) . The ETS domain is also involved in the fusion protein. The EWS/FLI-1 protein is mainly localized in the cell nucleus, and there is evidence that it functions as a transcription activator (Bailly et al., 1994) . The fusion protein has been found to be important for cell growth and tumor transformation (Tanaka et al., 1997; Toretsky et al., 1997) . Recently, Hahm et al. (1999) provided evidence that transformation growth factor-b type II receptor gene is a target for EWS/FLI-1. However, on the whole little is known about the target genes and how the expression of EWS/FLI-1 is regulated. We recently demonstrated that the fusion protein expression is dependent on the rate of N-linked glycosylation (Wang et al., 1999) . However, we could conclude that the fusion protein in itself if not a glycoprotein, even though it contains four potential sites for N-linked glycosylation. This suggests that certain glycoproteins may be important for EWS/FLI-1 expression. Most Nlinked glycoproteins, including growth factor receptors, are localized at the plasma membrane. It has been demonstrated that growth factor receptors require an adequate glycosylation to be translocated to the cell surface (Carlberg et al., 1996; Collier et al., 1993; Doyle et al., 1993) . So far comparatively few studies have investigated the role of growth factor pathways in Ewing's sarcoma cells. Most of these studies have been focusing on IGFs and IGFRs (Yee et al., 1990; van Valen et al., 1992; Hofbauer et al., 1993; Scotlandi et al., 1996) . In the study by Scotlandi et al. (1996) it was shown that the IGR-1R-mediated loop was constantly present in several Ewing's sarcoma cell lines and Ewing's sarcoma clinical samples. In a study by Toretsky et al. (1997) it was shown that the IGF-1 pathway is necessary for transformation of cells transfected with EWS/FLI-1 cDNA.
In the present study we investigated whether major growth factor circuits could be involved in EWS/FLI-1 protein expression in Ewing's sarcoma cells. Herewith, the role of epidermal growth factor (EGF), basic ®broblast growth factor (bFGF), insulin-like growth factor-1 (IGF-1), and platelet-derived growth factor (PDGF) was studied. Following a 24-h incubation of RD-ES cells in serum-free medium there was almost no EWS/FLI-1 protein detectable ( Figure 1a ). However, in the presence of bFGF the expression of the fusion gene product maintained at a normal level. Whereas IGF-1 had a weak eect, EGF and PDGF (when added alone) had no detectable eect. In Figure 1b it is shown that serum depletion also reduced DNA synthesis substantially. On the other hand, the cells survived for at least 1 week in serum-free medium and could be restimulated to growth by adding fresh serum (data not shown). After treatment with bFGF the serum-depleted cells proliferated almost at the same rate as the control cells (Figure 1b ). IGF-1 had also a positive eect but to a much lesser extent than bFGF. In contrast, PDGF and EGF were without eect. Coincubation of bFGF with any of the other growth factors did not increase the response.
In the next set of experiments we analysed the eect of a bFGF neutralizing antibody (GF22) on EWS/FLI-1 expression and cellular proliferation of RD-ES. It is well documented that this antibody prevents the interaction between bFGF and FGFRs (Hori et al., 1991) . We could demonstrate that a 24-h treatment with this antibody eciently inhibited the expression of the fusion protein (Figure 2a ). In Figure 2b it is shown that the bFGF antibody also arrested the cells. In this experiment it was also demonstrated that aIR-3, which prevents the binding of IGF-1 to its receptor (Kull et al., 1983) , only to a slight extent decreased the rate of DNA synthesis. To further investigate the speci®city of bFGF on EWS/ FLI-1, RD-ES cells were blocked in G1/S and G2/M using 2 mM thymidine and colcemide, respectively. It was con®rmed that these inhibitors blocked cell proliferation properly (data not shown). As shown in Figure  2c , cells blocked by thymidine and colcemide showed an equal expression of EWS/FLI-1 compared to growing in +Se medium were treated with 2 mM thymidine or colcemide (400 ng/ml) to block the cells in G1/S and G2/M, respectively. After 24 h bFGFab (0.2 mg/ml) was added to one subset of the cultures, whereas no compound was added to the other. After incubation overnight the expression of EWS/FLI-1 protein was analysed. The control represents unblocked growing cells. The experiments were repeated with similar results Oncogene bFGF and EWS/FLI-1 L Girnita et al control cells. However, if bFGF antibody was added the signals were drastically reduced (Figure 2c ). Taken together, our data suggest a direct link between bFGF and EWS/FLI-1 expression.
We now investigated the expression of FGFRs at the cell surface of RD-ES cells in comparison to prostatic carcinoma cells (PC), which functions as a positive control for FGFR expression (Takahashi, 1998) , and normal human ®broblasts (HDF) (Figure 3a) . Western blot analysis using the FGFR antibody GR21, which is reactive to FGFR1-3, was performed. Both PC and RD-ES exhibited a clear signal with a molecular size of approximately 120 kDa, which corresponds with the size of FGFRs. In contrast, we could not detect any receptor protein in HDF. In order to investigate whether this ®nding could be of general impact for Ewing's sarcoma, we analysed tumor samples derived from eight dierent patients with Ewing's sarcoma. Figure 3b shows that all cases, with the exception of one, expressed detectable amounts of FGFRs. This indicates that FGFRs may be commonly expressed in Ewing's sarcoma. We also analysed autophosphorylation of FGFR in RD-ES cells. In the control cells there was a clear positive signal corresponding to FGFRs (Figure 3 ). This signal disappeared in cells depleted of serum for 24 h. If the serum-free medium was supplemented with bFGF, receptor phosphorylation remained high but was completely abrogated by the bFGF antibody (Figure 3c ).
Among the dierent types of FGFRs, FGFR1 and FGFR2 in particular are implicated in cancer (Klint and Claesson-Welch, 1999) . Using RT ± PCR for detection of FGFR1 and FGFR2 transcripts in RD-ES cells, only signals for FGFR1 were found ( Figure  3d ). The same result was obtained in another Ewing's sarcoma cell line, ES-1. Both these cell lines were also found to express bFGF (Figure 3e) . Apparently, the amount of bFGF produced by the tumor cells is not sucient for stimulating induction of EWS/FLI-1 and cell growth under serum-free conditions (c.f. Figure 1) .
Finally, we investigated the eect of the bFGF antibody on EWS/FLI-1 in three other Ewing's sarcoma cell lines (ES-1, ET-3 and ET-8), in comparison with RD-ES. We could con®rm that this treatment downregulated the fusion protein in all these cell lines Membrane proteins were prepared by centrifugation of the cell material at 17 300 g as described by Gammeltoft (1991) , and SDS ± PAGE and Western blotting using a mouse anticlonal antibody to human FGFR (Ab-1, GR21, Oncogene Science) was performed. The same amount of proteins was loaded for each sample. (b) Eight dierent samples (no 1 ± 8) from Ewing's sarcoma biopsies were analysed for expression of FGFR. Equivalent amount of plasma membrane proteins from HDF was analysed simultaneously. (c) Autophosphorylation of FGFR. RD-ES cells remained either in +Se medium or were transferred to 7Se medium containing no growth factors or bFGF (20 ng/ml) or bFGF+bFGFab (0.2 mg/ml). After 24 h immunoprecipitation with the FGFR antibody was run. Thereafter Western blotting using an antibody against phosphotyrosine (PY99) (Santa Cruz) was performed. (d) Detection of FGFR transcripts. RNA was isolated from RD-ES and ES cells. RT ± PCR using primers for FGFR1 (forward, CGGTGTGCCTGTGGAG-GAACTT; reverse, GTTACAGCTGACGGTGGAGTCT) and FGFR2 (forward, GGTCGTTT-CATCTGCCTGGTCG; reverse, TGGCGCCCTTTATCTGCA-AGTA), as well as primers for actin, was carried out as described (Jayson et al., 1999) . The lanes are speci®ed on the right. (e) Detection of bFGF. Total proteins were isolated from RD-ES and ES-1 cells (ATCC). Western blotting using bFGFab was performed. Commercial bFGF (4 ng) was used as control (Figure 4 ). The eect varied from 65% to 91% (mean 77%) between the cell lines. High-anity FGFRs (FGFR1, FGFR2, FGFR3 and FGFR4) are encoded by separate genes, but there are several isoforms due to alternative splicing (Galzie et al., 1997; Klagsbrun and Baird, 1991) . The biological signi®cance for all these variants is still not clear. All FGFRs contain an extracellular domain made up of 2 ± 3 immunoglobulin-like repeats, a transmembrane domain and a cytoplasmic tyrosine kinase domain (Galzie et al., 1997) . It is believed that the bFGF-FGFR interaction outside the cell, which is facilitated by heparan sulphate proteoglycans (Klagsbrun and Baird, 1991) , leads to receptor dimerization, whereupon tyrosine phosphorylation of the receptors and receptor target proteins occurs. Since EWS/FLI-1 is important for transformation and growth of Ewing's sarcoma cells, further characterization of the molecular mechanisms underlying the link between FGFR and EWS/FLI-1 is of interest. Such studies are in progress in our laboratory.
